Clinical Trials Events Legalization Safety 
Cannabis Law Report
JUNE 1, 2021
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 8, 2021
These statements relate to future events or future performance. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
The Joint Blog
APRIL 17, 2020
And with the legalization of cannabis in Canada and legislation in 33 US states allowing for some kind of marijuana use (recreational or medicinal), the popularity of cannabis has been on the rise. Reported adverse effect in many clinical trials included amnesia, impaired balance, disturbed attention, dizziness, lethargy, and somnolence.
Cannabis Law Report
JULY 24, 2021
The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.
Cannabis Law Report
JANUARY 26, 2022
The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.
Cannabis Law Report
JANUARY 12, 2022
As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. We don’t believe safety and access are opposing polarities that must be constantly balanced.
Expert insights. Personalized for you.
89 
Let's personalize your content